Fideuram Intesa Sanpaolo Private Banking S.P.A. Acquires New Position in DexCom, Inc. $DXCM

Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) during the fourth quarter, Holdings Channel.com reports. The fund acquired 28,001 shares of the medical device company’s stock, valued at approximately $1,858,000.

Several other large investors also recently added to or reduced their stakes in DXCM. Holocene Advisors LP bought a new stake in DexCom in the third quarter worth approximately $163,964,000. CIBC Private Wealth Group LLC grew its position in DexCom by 374.3% in the third quarter. CIBC Private Wealth Group LLC now owns 2,907,801 shares of the medical device company’s stock worth $195,666,000 after acquiring an additional 2,294,709 shares in the last quarter. Vanguard Group Inc. grew its position in DexCom by 2.3% in the third quarter. Vanguard Group Inc. now owns 49,456,043 shares of the medical device company’s stock worth $3,327,897,000 after acquiring an additional 1,133,638 shares in the last quarter. Iron Triangle Partners LP bought a new stake in DexCom in the third quarter worth approximately $57,196,000. Finally, DNB Asset Management AS grew its position in DexCom by 271.8% in the third quarter. DNB Asset Management AS now owns 1,098,544 shares of the medical device company’s stock worth $73,921,000 after acquiring an additional 803,086 shares in the last quarter. 97.75% of the stock is owned by institutional investors.

Analysts Set New Price Targets

DXCM has been the subject of several recent research reports. Wells Fargo & Company decreased their target price on shares of DexCom from $93.00 to $85.00 and set an “overweight” rating for the company in a research report on Friday, February 13th. BTIG Research reissued a “buy” rating and issued a $85.00 target price on shares of DexCom in a research report on Monday, March 9th. Benchmark initiated coverage on shares of DexCom in a research report on Monday, May 11th. They issued a “buy” rating and a $77.00 target price for the company. Piper Sandler reissued an “overweight” rating on shares of DexCom in a research report on Thursday, February 5th. Finally, Bank of America decreased their target price on shares of DexCom from $100.00 to $80.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Three analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $82.21.

Insiders Place Their Bets

In other news, Director Bridgette P. Heller sold 1,012 shares of the business’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total value of $60,730.12. Following the completion of the sale, the director directly owned 25,007 shares in the company, valued at approximately $1,500,670.07. The trade was a 3.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the business’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $59.91, for a total transaction of $101,847.00. Following the completion of the sale, the executive vice president owned 109,504 shares of the company’s stock, valued at $6,560,384.64. The trade was a 1.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 6,112 shares of company stock valued at $379,990 over the last 90 days. 0.28% of the stock is owned by corporate insiders.

DexCom Price Performance

Shares of DexCom stock opened at $72.10 on Friday. The firm has a fifty day simple moving average of $63.58 and a 200-day simple moving average of $65.98. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $89.98. The stock has a market capitalization of $27.82 billion, a price-to-earnings ratio of 30.81, a PEG ratio of 1.19 and a beta of 1.40.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The business had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same period in the previous year, the company earned $0.32 earnings per share. DexCom’s revenue for the quarter was up 15.0% on a year-over-year basis. On average, sell-side analysts expect that DexCom, Inc. will post 2.57 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.